PMID- 12235924
OWN - NLM
STAT- MEDLINE
DCOM- 20030305
LR  - 20170214
IS  - 0300-0605 (Print)
IS  - 0300-0605 (Linking)
VI  - 30
IP  - 4
DP  - 2002 Jul-Aug
TI  - Polymorphism of CYP2C19 and gastric emptying in patients with proton pump 
      inhibitor-resistant gastric ulcers.
PG  - 413-21
AB  - The aim of the present study was to investigate whether CYP2C19 polymorphism 
      status and gastric emptying are related to healing in patients with gastric 
      ulcers. We studied the CYP2C19 status in seven patients with proton pump 
      inhibitor (PPI)-resistant ulcers, 21 with PPI-sensitive ulcers and 46 healthy 
      volunteers using polymerase chain reaction restriction fragment length 
      polymorphism to detect CYP2C19m1 mutation in exon 5 and CYP2C19m2 mutation in 
      exon 4. Gastric emptying was evaluated using the 13C-acetate breath test. The 
      frequency of phenotypes, indicated by genotypes, did not differ significantly 
      between the three patient groups. The peak time of 13C excretion in patients with 
      PPI-resistant ulcers was significantly longer than that of patients with 
      PPI-sensitive ulcers and healthy volunteers. Our results suggest that rate of 
      gastric emptying, but not CYP2C19 polymorphism, is likely to be an important 
      factor in the delayed healing of patients with PPI-resistant gastric ulcer.
FAU - Wada, F
AU  - Wada F
AD  - Second Department of Internal Medicine, Nagasaki University School of Medicine, 
      Nagasaki, Japan.
FAU - Murase, K
AU  - Murase K
FAU - Isomoto, H
AU  - Isomoto H
FAU - Soda, H
AU  - Soda H
FAU - Takeshima, F
AU  - Takeshima F
FAU - Omagari, K
AU  - Omagari K
FAU - Mizuta, Y
AU  - Mizuta Y
FAU - Tsukamoto, K
AU  - Tsukamoto K
FAU - Murata, I
AU  - Murata I
FAU - Kohno, S
AU  - Kohno S
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Int Med Res
JT  - The Journal of international medical research
JID - 0346411
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Benzimidazoles)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0K5C5T2QPG (Lansoprazole)
RN  - 32828355LL (Rabeprazole)
RN  - EC 1.- (Mixed Function Oxygenases)
RN  - EC 1.14.14.1 (Aryl Hydrocarbon Hydroxylases)
RN  - EC 1.14.14.1 (CYP2C19 protein, human)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP2C19)
RN  - KG60484QX9 (Omeprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles
MH  - Adult
MH  - Anti-Ulcer Agents/therapeutic use
MH  - Aryl Hydrocarbon Hydroxylases/*genetics/physiology
MH  - Benzimidazoles/therapeutic use
MH  - Cytochrome P-450 CYP2C19
MH  - Female
MH  - Gastric Emptying/genetics/*physiology
MH  - Humans
MH  - Lansoprazole
MH  - Male
MH  - Middle Aged
MH  - Mixed Function Oxygenases/*genetics/physiology
MH  - Omeprazole/*analogs & derivatives/therapeutic use
MH  - Polymorphism, Genetic/physiology
MH  - *Proton Pump Inhibitors
MH  - Rabeprazole
MH  - Stomach Ulcer/drug therapy/enzymology/*genetics/physiopathology
EDAT- 2002/09/19 10:00
MHDA- 2003/03/06 04:00
CRDT- 2002/09/19 10:00
PHST- 2002/09/19 10:00 [pubmed]
PHST- 2003/03/06 04:00 [medline]
PHST- 2002/09/19 10:00 [entrez]
AID - 10.1177/147323000203000408 [doi]
PST - ppublish
SO  - J Int Med Res. 2002 Jul-Aug;30(4):413-21. doi: 10.1177/147323000203000408.